ROCHE HOLDING LTD
Known title: 10% OwnerCIK: 0000889131
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
TRDA sees institutional interest from NVIDIA and Merck. The Benzinga report notes that institutional investors linked to NVIDIA and Merck have increased their positions in TRDA. This activity signals growing confidence in the company’s pipeline and may attract additional attention from other investors. The move comes as TRDA trades near the lower end of its 52‑week range, providing a potential entry point for those monitoring the stock.
Transaction History
| JSPR | ▼ Sell | Open Market | 75,000 | $142K | 1/25/2023 | View on chart |
| TRDA | ▼ Sell | Other | 318,140 | — | 11/2/2021 | View on chart |
| TRDA | ▼ Sell | Other | 2,495,385 | — | 11/2/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
Jasper Therapeutics Names Interim CFO
Jasper Therapeutics announced that Herb Cross will resign as Chief Financial Officer effective October 9, 2026. Jeet Mahal has been appointed as the interim Principal Financial Officer to take over the role. This leadership change occurs while the stock trades well below its 52-week high and near recent support levels.
Jasper Therapeutics Names Interim CFO. Jasper Therapeutics announced that Herb Cross will resign as Chief Financial Officer effective October 9, 2026. Jeet Mahal has been appointed as the interim Principal Financial Officer to take over the role. This leadership change occurs while the stock trades well below its 52-week high and near recent support levels.